Skip to main content Accessibility help
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 2
  • Print publication year: 2010
  • Online publication date: December 2010

3 - Flow cytometry

from Part 1 - Diagnostic techniques
Bourner, G, Dhaliwal, J, Sumner, JPerformance evaluation of the latest fully automated hematology analyzers in a large, commercial laboratory setting: a 4-way, side-by-side study. Lab Hematol 2005;11(4):285–97.
Stetler-Stevenson, MAE, Barnett, D, Braylan, RCet al. Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells; Approved Guideline, 2nd Edn. CLSI document H43-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2005.
Braylan, RC, Orfao, A, Borowitz, MJ, Davis, BH. Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. Cytometry. 2001;461(1):23–7.
Wood, B.Nine-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med 2006;130(5):680–90.
Weir, EG, Cowan, K, LeBeau, P, Borowitz, MJ. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four-color flow cytometry: implications for residual disease detection. Leukemia 1999;13(4):558–67.
Davis, BH, Holden, JT, Bene, MCet al. 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications. Cytometry B Clin Cytom 2007;72 Suppl. 1:S5–13.
Orfao, A, Ortuno, F, Santiago, M, Lopez, A, San Miguel, JImmunophenotyping of acute leukemias and myelodysplastic syndromes. Cytometry A 2004;58(1):62–71.
Hegde, U, Filie, A, Little, RFet al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005;105(2):496–502.
Almasri, NM, Zaer, FS, Iturraspe, JA, Braylan, RC. Contribution of flow cytometry to the diagnosis of gastric lymphomas in endoscopic biopsy specimens. Mod Pathol 1997;10(7):650–6.
Mourad, WA, Tulbah, A, Shoukri, Met al. Primary diagnosis and REAL/WHO classification of non-Hodgkin's lymphoma by fine-needle aspiration: cytomorphologic and immunophenotypic approach. Diagn Cytopathol 2003;28(4):191–5.
Stetler-Stevenson, M, Arthur, DC, Jabbour, Net al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001;98(4):979–87.
Truong, F, Smith, BR, Stachurski, Det al. The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: a prospective study. Leuk Res 2009;33(8):1039–46.
Valent, P, Horny, HP, Bennett, JMet al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 2007;31(6):727–36.
Wells, DA, Benesch, M, Loken, MRet al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003;102(1):394–403.
DiGiuseppe, JA, Borowitz, MJ. Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin Oncol 1998;25(1):6–10.
Nowakowski, GS, Witzig, TE, Dingli, Det al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005;106(7):2276–9.
Ocqueteau, M, Orfao, A, Almeida, Jet al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998;152(6):1655–65.
Duggan, PR, Easton, D, Luider, J, Auer, IA. Bone marrow staging of patients with non-Hodgkin lymphoma by flow cytometry: correlation with morphology. Cancer 2000;88(4):894–9.
Del Poeta, G, Maurillo, L, Venditti, Aet al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001;98(9):2633–9.
Wiestner, A, Rosenwald, A, Barry, TSet al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101(12):4944–51.
Borowitz, MJ, Shuster, J, Carroll, AJet al. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study. Blood 1997;89(11):3960–6.
Jiang, L, Yuan, CM, Hubacheck, Jet al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol 2009;145(2):173–9.
Perz, J, Topaly, J, Fruehauf, S, Hensel, M, Ho, AD. Level of CD20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leukemia Lymphoma 2002;43(1):149–51.
Coustan-Smith, E, Sancho, J, Hancock, MLet al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96(8):2691–6.
Rawstron, AC, Kennedy, B, Evans, PAet al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001;98(1):29–35.
Kraan, J, Gratama, JW, Haioun, Cet al. Flow cytometric immunophenotyping of cerebrospinal fluid. Curr Protoc Cytom 2008;Chapter 6:Unit 6.25.
Wood, BL, Arroz, M, Barnett, Det al. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytom B Clin Cytom 2007;72 Suppl. 1:S14–22.
Jaffe, ES, Harris, NL, Stein, H, Vardiman, JW.Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Kleihues, PSL (ed.). Lyon: IARC Press; 2001.
Weir, EG, Borowitz, MJ. Flow cytometry in the diagnosis of acute leukemia. Semin Hematol 2001;38(2):124–38.
Borowitz, MJ, Rubnitz, J, Nash, M, Pullen, DJ, Camitta, B.Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study. Leukemia 1998;12(11):1764–70.
Zen, L, Orfao, A, Cazzaniga, Get al.Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: correlation with specific genotype. I. ETV6/AML1 ALLs identification. Leukemia 2000;14(7):1225–31.
Lee, RV, Braylan, R C, Rimsza, LM. CD58 expression decreases as nonmalignant B cells mature in bone marrow and is frequently overexpressed in adult and pediatric precursor B-cell acute lymphoblastic leukemia. Am J Clin Pathol 2005;123(1):119–24.
Davis, RE, Longacre, TA, Cornbleet, PJ. Hematogones in the bone marrow of adults. Immunophenotypic features, clinical settings and differential diagnosis. Am J Clin Pathol 1994;102:202–11.
Dunphy, CH. Comprehensive review of adult acute myelogenous leukemia: cytomorphological, enzyme cytochemical, flow cytometric immunophenotypic, and cytogenetic findings. J Clin Lab Analysis 1999;13(1):19–26.
Li, S, Juco, J, Mann, KP, Holden, JT. Flow cytometry in the differential diagnosis of lymphocyte-rich thymoma from precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. Am J Clin Pathol 2004;121(2):268–74.
Gorczyca, W, Tugulea, S, Liu, Zet al. Flow cytometry in the diagnosis of mediastinal tumors with emphasis on differentiating thymocytes from precursor T-lymphoblastic lymphoma/leukemia. Leukemia Lymphoma 2004;45(3):529–38.
Raza, A, Jurcic, JG, Roboz, GJet al. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leukemia Lymphoma 2009; 50:1336–44.
Hurwitz, CA, Raimondi, SC, Head, Det al. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood 1992;80(12):3182–8.
Baer, MR, Stewart, CC, Lawrence, Det al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 1997;90(4):1643–8.
Kita, K, Nakase, K, Miwa, Het al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 1992;80(2):470–7.
Orfao, A, Chillon, MC, Bortoluci, AMet al. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RAR alpha gene rearrangements. Haematologica 1999;84(5):405–12.
Lin, P, Hao, S, Medeiros, LJet al. Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis. Am J Clin Pathol 2004;121(3):402–7.
Kussick, SJ, Wood, BL.Using 4-color flow cytometry to identify abnormal myeloid populations. Arch Pathol Lab Med 2003;127(9):1140–7.
Kussick, SJ, Wood, BL. Four-color flow cytometry identifies virtually all cytogenetically abnormal bone marrow samples in the workup of non-CML myeloproliferative disorders. Am J Clin Pathol 2003;120(6):854–65.
Stetler-Stevenson, M, Schrager, JA. Flow cytometric analysis in the diagnosis and prognosis of lymphoma and chronic leukemias. In McCoy, JP, Carey, JL, Keren, DF (eds.), Flow Cytometry in Clinical Diagnosis, 4th edn. Chicago: ASCP Press; 2006: 129–67.
Fukushima, PIN, Nguyen, PKT, O'Grady, P, Stetler-Stevenson, M. Flow cytometric analysis of kappa and lambda light chain expression in evaluation of specimens for B-cell neoplasia. Cytometry 1996;26:243–52.
Kussick, S, Kalnoski, M, Braziel, R, Wood, B. Prominent clonal B-cell populations identified by flow cytometry in histologically reactive lymphoid proliferations. Am J Clin Pathol 2004;121:464–72.
Marti, G, Rawstron, AC, Ghia, Pet al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 2005;130:325–32.
Rawstron, A, Green, MJ, Kuzmicki, Aet al. Monoclonal B lymphocytes with the characteristics of indolent chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002;100:635–9.
Maiese, RL, Segal, GH, Iturraspe, JA, Braylan, RC. The cell-surface antigen and DNA content distribution of lymph-nodes with reactive hyperplasia. Modern Pathol 1995;8(5):536–43.
Huang, J, Fan, G, Zhong, Yet al. Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry. Am J Clin Pathol 2005;123:826–32.
Kaleem, Z, Zehnbauer, BA, White, G, Zutter, MM. Lack of expression of surface immunoglobulin light chains in B-cell non-Hodgkin lymphomas. Am J Clin Pathol 2000;113(3):399–405.
Li, S, Eshleman, JR, Borowitz, MJ. Lack of surface immunoglobulin light chain expression by flow cytometric immunophenotyping can help diagnose peripheral B cell lymphoma. Am J Clin Pathol 2002;118:229–34.
Cornfield, DB, Mitchell, DM, Almasri, NMet al. Follicular lymphoma can be distinguished from benign follicular hyperplasia by flow cytometry using simultaneous staining of cytoplasmic bcl-2 and cell surface CD20. Am J Clin Pathol 2000;114(2):258–63.
Almasri, NM, Iturraspe, JA, Braylan, RC. CD10 expression in follicular lymphoma and large cell lymphoma is different from that of reactive lymph node follicles. Archives Pathol Lab Med 1998;122(6):539–44.
Chen, X, Jensen, PE, Li, S. HLA-DO – A useful marker to distinguish florid follicular hyperplasia from follicular lymphoma by flow cytometry. Am J Clin Pathol 2003;119(6):842–51.
Ginaldi, L, Martinis, M, Matutes, E, Farahat, N, Morilla, R. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998; 51:364–9.
Yang, W, Agrawal, N, Patel, Jet al. Diminished expression of CD19 in B-cell lymphomas. Cytom B Clin Cytom 2005;63B:28–35.
Kingma, DW, Imus, P, Xie, XYet al. CD2 is expressed by a sub-population of normal B cells and is frequently present in mature B-Cell neoplasms. Clin Cytom 2002;50:243–8.
Kaleem, Z, White, G, Zutter, MM. Aberrant expression of T-cell-associated antigens on B-cell non-Hodgkin lymphoma. Am J Clin Pathol 2001;115:396–403.
Foran, J, Norton, AJ, Micallef, INMet al. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD-20): a retrospective cohort analysis. Br J Haematol 2001;114:881–3.
Rawstron, AC, Orfao, A, Beksac, Met al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008;93(3):431–8.
Ocqueteau, M, Orfao, A, Almeida, Jet al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998;152:1655–65.
Almeida, J, Orfao, A, Ocqueteau, Met al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol 1999;107:121–31.
Konoplev, S, Medeiros, LJ, Bueso-Ramos, CE, Jorgensen, JL, Lin, P. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Am J Clin Pathol 2005;124:414–20.
Lin, P, Owens, R, Tricot, G, Wilson, CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004;121:482–8.
Rawstron, AC, Davies, FE, DasGupta, Ret al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002;100(9):3095–100.
Mateo, G, Montalban, MA, Vidriales, MBet al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008;26(16):2737–44.
Gorczyca, W, Weisberger, J, Liu, Zet al. An approach to diagnosis of T-cell lymphoproliferative disorders by flow cytometry. Clinical Cytometry 2002;50B:177–90.
Nicholson, JK, Rao, PE, Calvelli, Tet al. Artifactual staining of monoclonal antibodies in two-color combinations is due to an immunoglobulin in the serum and plasma. Cytometry 1994;18(3):140–6.
McClanahan, J, Fukushima, PI, Stetler-Stevenson, M.Increased peripheral blood gamma delta T-cells in patients with lymphoid neoplasia: A diagnostic dilemma in flow cytometry. Cytometry 1999;38(6):280–5.
Lima, M, Teixeira, MD, Queiros, MLet al. Immunophenotype and TCR-V beta repertoire of peripheral blood T-cells in acute infectious mononucleosis. Blood Cells Molecules Diseases 2003;10:1–12.
Jamal, S, Picker, LJ, Aquino, DBet al. Immunophenotypic analysis of peripheral T-cell neoplasms. A multiparameter flow cytometric approach. Am J Clin Pathol 2001;116:512–26.
Edelman, J, Meyerson, HJ. Diminished CD3 expression is useful for detecting and enumerating Sézary cells. Am J Clin Pathol 2000;114(3):467–77.
Yokote, T, Akioka, T, Oka, Set al. Flow cytometric immunophenotyping of adult T-cell leukemia/lymphoma using CD3 gating. Am J Clin Pathol 2005;124(2):199–204.
Li, Y, Braylan, RC, Al-Quran, SZ. Flow-cytometric assessment of T-cell clonality in clinical specimens. LabMed 2007;38(8):477–82.
Beemd, RB, Boor, PPC, Lochem, EGet al. Flow cytometric analysis of the V beta repertoire in healthy controls. Cytometry 2000;40(4):336–45.
Ferenczi, K, Yawalkar, N, Jones, D, Kupper, TS. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy. Archives of Dermatology 2003;139(7):909–13.
Morice, WG, Katzmann, JA, Pittelkow, MRet al. A comparison of morphologic features, flow cytometry, TCR-V-beta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sezary syndrome. Am J Clin Pathol 2006;125(3):364–74.
Lima, M, Almeida, J, Montero, AGet al. Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56-/+dim chronic natural killer cell large granular lymphocytosis. Am J Pathol 2004;165(4):1117–27.
Husain, Z, Alper, CA, Yunis, EJ, Dubey, DP. Complex expression of natural killer receptor genes in single natural killer cells. Immunology 2002;106(3):373–80.
Epling-Burnette, PK, Painter, JS, Chaurasia, Pet al. Dysregulated NK receptor expression in patients with lymphoproliferative disease of granular lymphocytes. Blood 2004;103(9):3431–9.
Pascal, V, Schleinitz, N, Brunet, Cet al. Comparative analysis of NK cell subset distribution in normal and lymphoproliferative disease of granular lymphocyte conditions. European J Immunol 2004;34(10):2930–40.
Sawada, A, Sato, E, Koyama, Met al. NK-cell repertoire is feasible for diagnosing Epstein-Barr virus-infected NK-cell lymphoproliferative disease and evaluating the treatment effect. Am J Hematol 2006;81(8):576–81.
Kussick, SJ, Fromm, JR, Rossini, Aet al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 2005;124(2):170–81.
Maynadie, M, Picard, F, Husson, Bet al. Immunophenotypic clustering of myelodysplastic syndromes. Blood 2002;100(7):2349–56.